{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:08:00Z","timestamp":1785550080787,"version":"3.56.0"},"reference-count":11,"publisher":"PAGEPress Publications","issue":"2","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>Psoriasis is a chronic immune-mediated disease primarily affecting the skin. The most common subtype is plaque psoriasis, which can affect any body area, with a predilection for the knees, elbows, scalp, lumbosacral region, and genitalia. The European guidelines adopted in Italy recommend systemic therapies for moderate-to-severe psoriasis, defined by a Psoriasis Area and Severity Index (PASI) \u226510, Dermatology Life Quality Index (DLQI) \u226510, and\/or Body Surface Area (BSA) \u226510. Over the past two decades, the development of biological agents has revolutionized psoriasis management, targeting specific cytokines, including tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-23, and IL-17. Among these, ixekizumab, secukinumab, brodalumab, and bimekizumab are approved for the treatment of moderate-to-severe plaque psoriasis. However, some patients require switching therapy because of primary\/secondary ineffectiveness or side effects. We retrospectively analyzed 20 patients who had switched from one anti-IL-17 drug to another, assessing both safety and effectiveness. At baseline, the median PASI score was 10 (interquartile range [IQR] 4.5). After 16 weeks, it decreased to 2 (IQR 5.5), and after one year, it decreased further to 1 (IQR 2). Eight (40%) and six patients (30%) achieved PASI 90 and PASI 100 at 16 weeks, respectively. After one year, sustained effectiveness was observed, with PASI 90 (57.1%), PASI 100 (35.7%), and PASI\u22642 (78.6%). No serious adverse events (AEs) or discontinuations due to AEs were observed during the study period. Our study confirms the safety and effectiveness of intra-class switching among IL-17 antagonists within the same class and highlights that switching between different classes of IL-17 inhibitors can be a valid option when patients fail to respond or lose effectiveness with a particular inhibitor. However, a deeper understanding requires further large-scale and long-term studies.<\/jats:p>","DOI":"10.4081\/dr.2024.10080","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T03:07:11Z","timestamp":1731380831000},"source":"Crossref","is-referenced-by-count":5,"title":["Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience"],"prefix":"10.4081","volume":"17","author":[{"given":"Gioele","family":"Ghezzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"27604","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"27605","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16915"},{"key":"27606","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207488"},{"key":"27607","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub4"},{"key":"27608","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17115"},{"key":"27609","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2199108"},{"key":"27610","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01182-4"},{"key":"27611","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01907-y"},{"key":"27612","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.085"},{"key":"27613","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18381"},{"key":"27614","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01271-w"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10080\/9486","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10080\/9686","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10080\/9486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:32:14Z","timestamp":1774002734000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.4081\/dr.2024.10080","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,12]]}}}